Universal Beteiligungs und Servicegesellschaft mbH Acquires New Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 143,952 shares of the company's stock, valued at approximately $6,521,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.32% of Apogee Therapeutics at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new stake in shares of Apogee Therapeutics during the fourth quarter worth about $43,000. Neo Ivy Capital Management acquired a new position in Apogee Therapeutics during the 4th quarter valued at about $1,745,000. Woodline Partners LP increased its holdings in Apogee Therapeutics by 4.0% during the 4th quarter. Woodline Partners LP now owns 1,015,608 shares of the company's stock worth $46,007,000 after purchasing an additional 39,453 shares in the last quarter. Soleus Capital Management L.P. purchased a new stake in shares of Apogee Therapeutics in the fourth quarter worth approximately $3,171,000. Finally, Squarepoint Ops LLC raised its stake in shares of Apogee Therapeutics by 90.9% in the fourth quarter. Squarepoint Ops LLC now owns 36,344 shares of the company's stock worth $1,646,000 after purchasing an additional 17,301 shares during the last quarter. Institutional investors and hedge funds own 79.04% of the company's stock.

Apogee Therapeutics Price Performance

Shares of NASDAQ APGE traded down $0.58 during midday trading on Wednesday, reaching $36.50. The company's stock had a trading volume of 1,175,237 shares, compared to its average volume of 534,000. The stock has a market capitalization of $1.68 billion, a P/E ratio of -15.08 and a beta of 1.70. The firm has a 50 day moving average price of $36.28 and a 200-day moving average price of $39.63. Apogee Therapeutics, Inc. has a 12-month low of $26.20 and a 12-month high of $63.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.95) EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $0.24. On average, equities analysts predict that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on APGE. Wedbush reiterated an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Finally, Citigroup assumed coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $95.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $94.60.

Insider Activity

In related news, insider Carl Dambkowski sold 3,860 shares of the business's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $36.22, for a total value of $139,809.20. Following the transaction, the insider now directly owns 247,173 shares of the company's stock, valued at approximately $8,952,606.06. The trade was a 1.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 42.77% of the company's stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.